Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

HonorHealth Research Institute

13 clinical trials

13 abstracts

Abstract
Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.
Org: Sylvester Comprehensive Cancer Center, University of Miami Health System, The University of Texas MD Anderson Cancer Center, HonorHealth Research Institute, University of California, San Francisco, Baylor College of Medicine,
Abstract
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.
Org: National Cancer Center Hospital Japan East, St. Marianna University School of Medicine, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Seoul National University College of Medicine, HonorHealth Research Institute,
Abstract
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Org: O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Clinical Trial Development Division, Roswell Park Comprehensive Cancer Center, Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, University of Oklahoma Health Sciences Center,
Abstract
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Org: US Oncology Research, HonorHealth Research Institute, Creighton University School of Medicine, The Ohio State University James Cancer Center, Division of Gynecologic Oncology,
Abstract
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Org: University of Arizona College of Medicine, European Institute of Oncology IRCCS, University of California Irvine, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Saitama Medical University International Medical Center,
Abstract
Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).
Org: HonorHealth Research Institute, Duke Cancer Institute, Chaim Sheba Medical Center, University of Cincinnati Cancer Institute, International Drug Development Institute,
Abstract
Racial disparities and survival outcome of patients with locally advanced cervix cancer in the international randomised phase 3 OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).
Org: NHMRC Clinical Trials Centre, The University of Sydney, Louisiana State University Health Sciences Center, Department of Gynecologic Oncology, University of California, Los Angeles,
Clinical trial
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)
Status: Completed, Estimated PCD: 2023-12-11
Clinical trial
A Phase II Trial of Vemurafenib in Combination With Sorafenib to Treat Patients With Advanced KRAS Mutated Pancreatic Cancer: Targeting RAF Dimers to Suppress Oncogenic RAS Signaling (The Dr. Nate Nieto Study)
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase II Pilot Clinical Trial of Lurbinectedin (Zepzelca™ PM01183) in Patients With Gastrointestinal Malignancies With DNA Repair Mutations
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Phase II Pilot Study of Disulfiram and Copper Gluconate in Patients With Metastatic Pancreatic Cancer and Rising CA-19-9 Levels While Receiving Abraxane-Gemcitabine or FOLFIRINOX or Single-Agent Gemcitabine
Status: Terminated, Estimated PCD: 2020-07-22
Clinical trial
An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab (AGEN1811) + Balsilimab (AGEN2034) + Chloroquine + Celecoxib in Patients With Previously Untreated Metastatic Pancreatic Cancer
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-04-11
Clinical trial
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Status: Active (not recruiting), Estimated PCD: 2023-05-23
Clinical trial
Efficacy and Safety of Pemigatinib in Subjects With Advanced Metastatic or Surgically Unresectable Adenosquamous Carcinoma of the Pancreas (ASCP) Who Have Progressed On Previous Therapy
Status: Withdrawn, Estimated PCD: 2024-08-31
Clinical trial
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2022-05-13
Clinical trial
Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer
Status: Completed, Estimated PCD: 2021-09-14
Clinical trial
Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance to Examine the Safety of Cessation of Dual Anti-Platelet Therapy in High Bleeding Risk Patients at One Month
Status: Active (not recruiting), Estimated PCD: 2021-12-31
Abstract
Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
Org: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI), University of Virginia, Charlottesville, VA, USA, University Hospitals Leuven, Leuven, Belgium, Institut du Cancer de Montpellier (ICM) Val d'Aurelle Parc Euromedecine,
Abstract
Dose optimization of novel BRAF inhibitor FORE8394 based on PK and efficacy results.
Org: Memorial Sloan Kettering Cancer Center, Sylvester Comprehensive Cancer Center, Miami, FL, HonorHealth Research Institute, MD Anderson Cancer Center, University of California Irvine,
Abstract
Phase 1 trial of GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.
Org: UPMC Hillman Cancer Center, HonorHealth Research Institute, City of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, University Hospital Siedman Cancer Center,
Abstract
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).
Org: College of Medicine, University of Cincinnati, Wexner Medical Center and The James Cancer Hospital, Ohio State University, Women's Cancer Care Associates, Arizona Oncology Associates, Texas Oncology - Fort Worth Cancer Center,
Abstract
ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.
Org: University Hospitals Leuven, Leuven, Belgium, Leuven Cancer Institute, BGOG, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Copenhagen University Hospital,
Abstract
Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, HonorHealth Research Institute, University of Miami Sylvester Comprehensive Cancer Center,